DiscoverThe BioInsights PodcastFor the many and the few: bringing ASO therapies to both mainstream and nano-rare indications
For the many and the few: bringing ASO therapies to both mainstream and nano-rare indications

For the many and the few: bringing ASO therapies to both mainstream and nano-rare indications

Update: 2025-03-13
Share

Description

Roisin McGuigan, Commissioning Editor, Nucleic Acid Insights, speaks to Stanley Crooke, Chairman, Founder and CEO, n-Lorem, about his long career and pioneering role in the antisense oligonucleotide (ASO) space, how RNA-targeting therapies are set to enter the mainstream, and his latest focus: making personalized, free-for-life ASO therapies available to nano-rare patient populations.

Comments 
loading
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

For the many and the few: bringing ASO therapies to both mainstream and nano-rare indications

For the many and the few: bringing ASO therapies to both mainstream and nano-rare indications

BioInsights